Enhancing preclinical drug discovery with artificial intelligence
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Artificial intelligence (AI) is becoming an integral part of drug discovery. It has the potential to deliver across the drug discovery and development value chain, starting from target identification and reaching through clinical development. In this review, we provide an overview of current AI technologies and a glimpse of how AI is reimagining preclinical drug discovery by highlighting examples where AI has made a real impact. Considering the excitement and hyperbole surrounding AI in drug discovery, we aim to present a realistic view by discussing both opportunities and challenges in adopting AI in drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057 · cited 1×
“One such implementation of active learning docking is ‘ Active Learning Glide ’ , 19 which integrates the docking program Glide 100 and the ML algorithms available from the open-source framework DeepChem.”
MethodUniProt: the universal protein knowledgebase in 2021
The UniProt Consortium, Bateman, A., Martin, M.-J., Orchard, S., Magrane, M., Agivetova, R., Ahmad, S., Alpi, E., Bowler-Barnett, E. H., Britto, R., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1100 · Cited by 6,372 · cited 1×
“46 Importantly, structural coverage for pharmaceutically relevant protein target families, such as G-protein-coupled receptors (GPCRs) and ion channels, remains underrepresented in databases, such as the Protein Data Bank (PDB).”
BackgroundAccurate prediction of protein structures and interactions using a 3-track network
Baek, M., DiMaio, F., Anishchenko, I., Dauparas, J., Ovchinnikov, S., Lee, G. R., Wang, J., Cong, Q., Kinch, L. N., Schaeffer, R. D., et al. (2021) · doi:10.1101/2021.06.14.448402 · Cited by 5,549 · cited 1×
“55 Although these developments signify advancements in protein structure prediction, it is too early to state that AI has cracked the protein-folding problem or its impact on drug discovery will be transformative.”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“20 It is inherently a multiparameter optimization (MPO) 21 problem, with the goal of identifying compounds with an optimal balance of drug-like properties while maintaining suf fi cient potency.”
BackgroundApplications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Highly accurate protein structure prediction for the human proteome
Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Žídek, A., Bridgland, A., Cowie, A., Meyer, C., Laydon, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03828-1 · Cited by 3,025 · cited 1×
“54 Inspired by the idea and the success of AlphaFold2, an academic team led by David Baker also developed a three-track NN program dubbed RoseTTAFold.”
Method
Research works printed but not linked: 100
- Wouters, 2020, Research and development costs of new drugs–reply, JAMA, 324, 518, 10.1001/jama.2020.8651 · DOI
- Mullard, 2021, 2020 FDA drug approvals, Nat Rev Drug Discov, 20, 85, 10.1038/d41573-021-00002-0 · DOI
- Brown, 2021, A decade of FDA-approved drugs (2010–2019): trends and future directions, J Med Chem, 64, 2312, 10.1021/acs.jmedchem.0c01516 · DOI · Paper page
- Schuhmacher, 2021, Big techs and startups in pharmaceutical R&D - a 2020 perspective on artificial intelligence, Drug Discov Today, 26, 2226, 10.1016/j.drudis.2021.04.028 · DOI
- Aoyama, 1990, Neural networks applied to pharmaceutical problems. III. Neural networks applied to quantitative structure-activity relationship (QSAR) analysis, J Med Chem, 33, 2583, 10.1021/jm00171a037 · DOI · Paper page
- Klingler, 1988, Expert systems in the pharmaceutical industry, Drug Info J, 22, 249, 10.1177/009286158802200217 · doi:10.1177/009286158802200217
- Plenge, 2016, Disciplined approach to drug discovery and early development, Sci Transl Med, 8, 349PS315, 10.1126/scitranslmed.aaf2608 · DOI · Paper page
- De Cesco, 2020, TargetDB: a target information aggregation tool and tractability predictor, PLoS ONE, 15, 10.1371/journal.pone.0232644 · DOI
- Vignaux, 2020, Machine learning for discovery of gsk3beta inhibitors, ACS Omega, 5, 26551, 10.1021/acsomega.0c03302 · DOI · Paper page
- McCloskey, 2020, Machine learning on DNA-encoded libraries: a new paradigm for hit finding, J Med Chem, 63, 8857, 10.1021/acs.jmedchem.0c00452 · DOI · Paper page
- Stork, 2019, Hit dexter 2.0: Machine-learning models for the prediction of frequent hitters, J Chem Inf Model, 59, 1030, 10.1021/acs.jcim.8b00677 · DOI · Paper page
- Graff, 2021, Accelerating high-throughput virtual screening through molecular pool-based active learning, Chem Sci, 12, 7866, 10.1039/D0SC06805E · DOI · Paper page
- Yang, 2021, Efficient exploration of chemical space with docking and deep-learning, J Chem Theory Comput, 17, 7106, 10.1021/acs.jctc.1c00810 · DOI · Paper page
- Segall, 2012, Multi-parameter optimization: identifying high quality compounds with a balance of properties, Curr Pharm Des, 18, 1292, 10.2174/138161212799436430 · DOI · Paper page
- Hann, 2012, Finding the sweet spot: the role of nature and nurture in medicinal chemistry, Nat Rev Drug Discov, 11, 355, 10.1038/nrd3701 · DOI · Paper page
- Bian, 2021, Generative chemistry: drug discovery with deep learning generative models, J Mol Model, 27, 71, 10.1007/s00894-021-04674-8 · DOI · Paper page
- Webb, 2010, Continuous flow multi-step organic synthesis, Chem Sci, 1, 675, 10.1039/c0sc00381f · DOI · Paper page
- Irwin, 2021, Deep imputation on large-scale drug discovery data, Applied AI Letters, 2, 10.1002/ail2.31 · DOI
- Whitehead, 2019, Imputation of assay bioactivity data using deep learning, J Chem Info Model, 59, 1197, 10.1021/acs.jcim.8b00768 · DOI · Paper page
- Irwin, 2020, Practical applications of deep learning to impute heterogeneous drug discovery data, J Chem Inf Model, 60, 2848, 10.1021/acs.jcim.0c00443 · DOI · Paper page
- Dolgos, 2016, Translational medicine guide transforms drug development processes: the recent Merck experience, Drug Discov Today, 21, 517, 10.1016/j.drudis.2016.01.003 · DOI
- Jimenez, 1998, Supervised classification in high-dimensional space: geometrical, statistical, and asymptotical properties of multivariate data, IEEE Trans Syst Man Cybern, Part C (Applications and Reviews), 28, 39, 10.1109/5326.661089 · DOI · Paper page
- Popova, 2018, Deep reinforcement learning for de novo drug design, Sci Adv, 4, eaap7885, 10.1126/sciadv.aap7885 · DOI · Paper page
- Gomes, J, Ramsundar, B, Feinberg, E.N, Pande, V.S. Atomic convolutional networks for predicting protein–ligand binding affinity. arXiv 2017: arXiv:1703.10603 2017. · arXiv
- Gupta, 2018, Generative recurrent networks for de novo drug design, Mol Info, 37, 170011
- Sellwood, 2018, Artificial intelligence in drug discovery, Future Med Chem, 10, 2025, 10.4155/fmc-2018-0212 · DOI · Paper page
- Edfeldt, 2011, Fragment screening to predict druggability (ligandability) and lead discovery success, Drug Discov Today, 16, 284, 10.1016/j.drudis.2011.02.002 · DOI · Paper page
- Vukovic, 2018, Quantitative metrics for drug-target ligandability, Drug Discov Today, 23, 1258, 10.1016/j.drudis.2018.02.015 · DOI
- Berman, 2000, The Protein Data Bank, Nucleic Acids Res, 28, 235, 10.1093/nar/28.1.235 · DOI · Paper page
- Hillisch, 2004, Utility of homology models in the drug discovery process, Drug Discov Today, 9, 659, 10.1016/S1359-6446(04)03196-4 · DOI · Paper page
- Kinch, 2019, CASP 13 target classification into tertiary structure prediction categories, Proteins, 87, 1021, 10.1002/prot.25775 · DOI · Paper page
- Jumper, J, Evans, R, Pritzel, A, Green, T, Figurnov, M, Tunyasuvunakool, K. et al. (2020) High accuracy protein structure prediction using deep learning. In Fourteenth Critical Assessment of Techniques for Protein Structure Prediction. Davis: Protein Structure Prediction Center; 2020: 22–24.
- Andreeva, 2020, The scop database in 2020: expanded classification of representative family and superfamily domains of known protein structures, Nucleic Acids Res, 48, D376, 10.1093/nar/gkz1064 · DOI · Paper page
- Grant, 2004, Progress towards mapping the universe of protein folds, Genome Biol, 5, 107, 10.1186/gb-2004-5-5-107 · DOI
- Ehrt, 2016, Impact of binding site comparisons on medicinal chemistry and rational molecular design, J Med Chem, 59, 4121, 10.1021/acs.jmedchem.6b00078 · DOI · Paper page
- Simonovsky, 2020, DeeplyTough: learning structural comparison of protein binding sites, J Chem Inf Model, 60, 2356, 10.1021/acs.jcim.9b00554 · DOI · Paper page
- Zhu, 2013, Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis, J Med Chem, 56, 6560, 10.1021/jm301916b · DOI · Paper page
- Ripphausen, 2010, Quo vadis, virtual screening? A comprehensive survey of prospective applications, J Med Chem, 53, 8461, 10.1021/jm101020z · DOI · Paper page
- Damm-Ganamet, 2019, Accelerating lead identification by high throughput virtual screening: prospective case studies from the pharmaceutical industry, J Chem Inf Model, 59, 2046, 10.1021/acs.jcim.8b00941 · DOI
- Gorgulla, 2020, An open-source drug discovery platform enables ultra-large virtual screens, Nature, 580, 663, 10.1038/s41586-020-2117-z · DOI · Paper page
- Wang, 2017, PubChem bioassay: 2017 update, Nucleic Acids Res, 45, D955, 10.1093/nar/gkw1118 · DOI · Paper page
- Mendez, 2019, ChEMBL: towards direct deposition of bioassay data, Nucleic Acids Res, 47, D930, 10.1093/nar/gky1075 · DOI · Paper page
- Zhang, 2013, Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening, J Chem Inf Model, 53, 475, 10.1021/ci300421n · DOI · Paper page
- Chen, 2020, Discovery of dual FGFR4 and EGFR inhibitors by machine learning and biological evaluation, J Chem Inf Model, 60, 4640, 10.1021/acs.jcim.0c00652 · DOI
- Donlin, 2021, Discovery of 5-nitro-6-thiocyanatopyrimidines as inhibitors of Cryptococcus neoformans and Cryptococcus gattii, ACS Med Chem Lett, 12, 774, 10.1021/acsmedchemlett.1c00038 · DOI
- Liu, 2021, Deep learning enables discovery of highly potent anti–osteoporosis natural products, Eur J Med Chem, 210, 10.1016/j.ejmech.2020.112982 · DOI
- Verkhivker, 2000, Deciphering common failures in molecular docking of ligand-protein complexes, J Comput Aided Mol Des, 14, 731, 10.1023/A:1008158231558 · DOI · Paper page
- Wicht, 2015, Bayesian models trained with HTS data for predicting beta-haematin inhibition and in vitro antimalarial activity, Bioorg Med Chem, 23, 5210, 10.1016/j.bmc.2014.12.020 · doi:10.1016/j.bmc.2014.12.020
- Yang, 2019, Machine learning models based on molecular fingerprints and an extreme gradient boosting method lead to the discovery of JAK2 inhibitors, J Chem Inf Model, 59, 5002, 10.1021/acs.jcim.9b00798 · DOI
- Liu, 2019, Deepscreening: a deep learning-based screening web server for accelerating drug discovery, Database (Oxford), 2019, baz104, 10.1093/database/baz104 · DOI
- Soufan, 2018, DPubChem: a web tool for qsar modeling and high-throughput virtual screening, Sci Rep, 8, 9110, 10.1038/s41598-018-27495-x · DOI
- Kitchen, 2004, Docking and scoring in virtual screening for drug discovery: methods and applications, Nat Rev Drug Discov, 3, 935, 10.1038/nrd1549 · DOI · Paper page
- Wallach, I, Dzamba, M, Heifets, A. AtomNet: a deep, convolutional neural network for bioactivity prediction in structure-based drug discovery. arXiv 2015: arXiv:1510.02855v1 · arXiv
- Gilson, 1997, The statistical-thermodynamic basis for computation of binding affinities: a critical review, Biophys J, 72, 1047, 10.1016/S0006-3495(97)78756-3 · DOI · Paper page
- Ashtawy, 2015, Machine-learning scoring functions for identifying native poses of ligands docked to known and novel proteins, BMC Bioinformatics, 16, S3, 10.1186/1471-2105-16-S6-S3 · DOI
- Bao, 2021, DeepBSP-a machine learning method for accurate prediction of protein-ligand docking structures, J Chem Inf Model, 61, 2231, 10.1021/acs.jcim.1c00334 · DOI
- Adeshina, 2020, Machine learning classification can reduce false positives in structure-based virtual screening, Proc Natl Acad Sci U S A, 117, 18477, 10.1073/pnas.2000585117 · DOI · Paper page
- Ballester, 2010, A machine learning approach to predicting protein-ligand binding affinity with applications to molecular docking, Bioinformatics, 26, 1169, 10.1093/bioinformatics/btq112 · DOI · Paper page
- Stepniewska-Dziubinska, 2018, Development and evaluation of a deep learning model for protein-ligand binding affinity prediction, Bioinformatics, 34, 3666, 10.1093/bioinformatics/bty374 · DOI · Paper page
- Zheng, 2019, Onionnet: A multiple-layer intermolecular-contact-based convolutional neural network for protein-ligand binding affinity prediction, ACS Omega, 4, 15956, 10.1021/acsomega.9b01997 · DOI · Paper page
- Durrant, 2011, NNScore 2.0: A neural-network receptor-ligand scoring function, J Chem Inf Model, 51, 2897, 10.1021/ci2003889 · DOI · Paper page
- Wang, 2017, Improving scoring-docking-screening powers of protein–ligand scoring functions using random forest, J Comput Chem, 38, 169, 10.1002/jcc.24667 · DOI · Paper page
- Shen, 2021, Can machine learning consistently improve the scoring power of classical scoring functions? Insights into the role of machine learning in scoring functions, Brief Bioinform, 22, 497, 10.1093/bib/bbz173 · DOI
- Benson, 2008, Binding MOAD, a high-quality protein-ligand database, Nucleic Acids Res, 36, D674, 10.1093/nar/gkm911 · DOI · Paper page
- Li, 2021, Machine-learning scoring functions for structure-based virtual screening, Wiley Interdiscip Rev Comput Mol Sci, 11, 10.1002/wcms.1478 · DOI · Paper page
- Sun, 2016, Constructing and validating high-performance miec–svm models in virtual screening for kinases: a better way for actives discovery, Sci Rep, 6, 24817, 10.1038/srep24817 · DOI
- Sieg, 2019, In need of bias control: evaluating chemical data for machine learning in structure-based virtual screening, J Chem Inf Model, 59, 947, 10.1021/acs.jcim.8b00712 · DOI · Paper page
- Clark, 2020, Virtual screening: Is bigger always better? Or can small be beautiful?, J Chem Info Model, 60, 4120, 10.1021/acs.jcim.0c00101 · DOI
- Darvas, 1974, Application of the sequential simplex method in designing drug analogs, J Med Chem, 17, 799, 10.1021/jm00254a004 · doi:10.1021/jm00254a004
- Bohm, 1992, Ludi: Rule-based automatic design of new substituents for enzyme inhibitor leads, J Comput Aided Mol Des, 6, 593, 10.1007/BF00126217 · DOI · Paper page
- Elbadawi, 2021, Advanced machine-learning techniques in drug discovery, Drug Discov Today, 26, 769, 10.1016/j.drudis.2020.12.003 · DOI · Paper page
- Meyers, 2021, De novo molecular design and generative models, Drug Discov Today, 26, 2707, 10.1016/j.drudis.2021.05.019 · DOI · Paper page
- Prykhodko, 2019, A de novo molecular generation method using latent vector based generative adversarial network, J Cheminform, 11, 74, 10.1186/s13321-019-0397-9 · DOI · Paper page
- Merk, 2018, Tuning artificial intelligence on the de novo design of natural-product-inspired retinoid x receptor modulators, Commun Chem, 1, 68, 10.1038/s42004-018-0068-1 · DOI · Paper page
- Zhavoronkov, 2020, Reply to ‘assessing the impact of generative ai on medicinal chemistry’, Nat Biotechnol, 38, 146, 10.1038/s41587-020-0417-3 · DOI
- Quentin, P, Olivier, M, Hamza, T, Adam, S, Anne, R, Arnaud, G. et al. Deep generative models for ligand-based de novo design applied to multi-parametric optimization. ChemRxiv. Published online January 25, 2021. http://dx.doi.org/10.26434/chemrxiv.13622417.v2. · doi:10.26434/chemrxiv.13622417.v2
- Young, 2011, Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity, Drug Discov Today, 16, 822, 10.1016/j.drudis.2011.06.001 · DOI · Paper page
- Martin, 2005, A bioavailability score, J Med Chem, 48, 3164, 10.1021/jm0492002 · DOI · Paper page
- van de Waterbeemd, 2003, ADMET in silico modelling: towards prediction paradise?, Nat Rev Drug Discov, 2, 192, 10.1038/nrd1032 · DOI · Paper page
- Lombardo, F, Desai, P.V, Arimoto, R, Desino, K.E, Fischer, H, Keefer, C.E. et al. In silico absorption, distribution, metabolism, excretion, and pharmacokinetics (ADME-PK): utility and best practices. An industry perspective from the international consortium for innovation through quality in pharmaceutical development. J Med Chem 2017; 60: 9097–9113. · DOI · Paper page
- Free, 1964, A mathematical contribution to structure-activity studies, J Med Chem, 7, 395, 10.1021/jm00334a001 · DOI · Paper page
- Sosnin, 2019, A survey of multi-task learning methods in chemoinformatics., Mol Inform, 38, 10.1002/minf.201800108 · DOI · Paper page
- Feinberg, 2020, Improvement in ADMET prediction with multitask deep featurization, J Med Chem, 63, 8835, 10.1021/acs.jmedchem.9b02187 · DOI · Paper page
- Wenzel, 2019, Predictive multitask deep neural network models for ADME-tox properties: learning from large data sets, J Chem Inf Model, 59, 1253, 10.1021/acs.jcim.8b00785 · DOI · Paper page
- Kenny, P.W, Sadowski, J. Structure modification in chemical databases. In: Oprea TI, ed. Chemoinformatics in Drug Discovery. Weinheim: Wiley–VHC Verlag GmbH & Co. KGaA; 2005: 271–285. · DOI · Paper page
- Kramer, 2018, Learning medicinal chemistry absorption, distribution, metabolism, excretion, and toxicity (ADMET) rules from cross-company matched molecular pairs analysis (MMPA), J Med Chem, 61, 3277, 10.1021/acs.jmedchem.7b00935 · DOI
- Corey, 1985, Computer-assisted analysis in organic synthesis, Science, 228, 408, 10.1126/science.3838594 · DOI · Paper page
- Corey, 1967, General methods for the construction of complex molecules, Pure Appl Chem, 14, 19, 10.1351/pac196714010019 · DOI · Paper page
- Plehiers, 2020, Artificial intelligence for computer-aided synthesis in flow: analysis and selection of reaction components, Front Chem Eng, 2, 5, 10.3389/fceng.2020.00005 · DOI
- Wang, 2021, Mapping the resources and approaches facilitating computer-aided synthesis planning, Org Chem Front, 8, 812, 10.1039/D0QO00946F · DOI
- Thakkar, 2021, Artificial intelligence and automation in computer aided synthesis planning, React Chem Eng, 6, 27, 10.1039/D0RE00340A · DOI · Paper page
- Dong, 2021, Deep learning in retrosynthesis planning: datasets, models and tools, Brief Bioinform, bbab391
- Struble, 2020, Current and future roles of artificial intelligence in medicinal chemistry synthesis, J Med Chem, 63, 8667, 10.1021/acs.jmedchem.9b02120 · DOI · Paper page
- Coley, 2017, Computer-assisted retrosynthesis based on molecular similarity, ACS Cent Sci., 3, 1237, 10.1021/acscentsci.7b00355 · DOI · Paper page
- Sacha, 2021, Molecule edit graph attention network: modeling chemical reactions as sequences of graph edits, J Chem Inf Model, 61, 3273, 10.1021/acs.jcim.1c00537 · DOI · Paper page
- Genheden, 2020, AiZynthFinder: a fast, robust and flexible open–source software for retrosynthetic planning, J Cheminform, 12, 70, 10.1186/s13321-020-00472-1 · DOI · Paper page
- Yan A. Ivanenkov, Y.A, Zhebrak, A, Bezrukov, D, Zagribelnyy, B, Aladinskiy, V, Polykovskiy, D, Putin, E, Kamya, P, Aliper, A, Zhavoronkov, A, Chemistry42: an AI-based platform for de novo molecular design. arXiv 2021: arXiv:2101.09050v1. · arXiv
- Klucznik, 2018, Efficient syntheses of diverse, medicinally relevant targets planned by computer and executed in the laboratory, Chem, 4, 522, 10.1016/j.chempr.2018.02.002 · DOI · Paper page
- Hu, 2012, Pfizer global virtual library (PGVL): a chemistry design tool powered by experimentally validated parallel synthesis information, ACS Comb Sci, 14, 579, 10.1021/co300096q · doi:10.1021/co300096q
- Mullard, 2017, The drug-maker’s guide to the galaxy, Nature, 549, 445, 10.1038/549445a · DOI
Cited by
Generative machine learning for de novo drug discovery: A systematic review
Martinelli, D. D. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105403 · Cited by 177
Explainable artificial intelligence for drug discovery and development: a comprehensive survey
Alizadehsani, R., Oyelere, S. S., Hussain, S., Jagatheesaperumal, S. K., Calixto, R. R., Rahouti, M., Roshanzamir, M., & De Albuquerque, V. H. C. (2024) · IEEE Access · doi:10.1109/access.2024.3373195 · Cited by 124
Bentwich, I. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103515 · Cited by 22
Metadata
- Authors
- Vijayan, R. S. K., Kihlberg, J., Cross, J. B., & Poongavanam, V.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 27
- Issue
- 4
- Pages
- 967-984
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W3217042593
- Cited by
- 180
- References
- 46
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Pfizer
- Wayne State University
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhancing preclinical drug discovery with artificial intelligence. https://app.cochat.ai/papers/10.1016/j.drudis.2021.11.023
- The paper
- Vijayan, R. S. K., Kihlberg, J., Cross, J. B., & Poongavanam, V. (2022). Enhancing preclinical drug discovery with artificial intelligence. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2021.11.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.